PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
公司动态 - PureTech旗下创立的实体Gallop Oncology宣布了其候选药物LYT-200在复发/难治性急性髓系白血病中获得了积极的初步顶线数据 [1] 产品研发进展 - 候选药物LYT-200针对的适应症为复发/难治性急性髓系白血病 [1] - 公布的数据类型为初步顶线数据，数据结果为积极 [1]